{"nctId":"NCT01600703","briefTitle":"Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans","startDateStruct":{"date":"2012-07"},"conditions":["Hyperlipidemia"],"count":21,"armGroups":[{"label":"Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Sitagliptin","otherNames":["Januvia"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Men and women, aged 18 to 60 years\n2. Body mass index 20 kg/m2 to 27 kg/m2\n3. Hemoglobin above 130g/L.\n4. Normal glucose tolerance in response to a 75g, 2-hr OGTT\n\nExclusion Criteria:\n\n1. Subject has a history of hepatitis/hepatic disease that has been active within the previous two years.\n2. Any significant active (over the past 12 months) disease of the gastrointestinal, pulmonary, neurological, renal (Cr \\> 1.5 mg/dL), genitourinary, hematological systems, or has severe uncontrolled treated or untreated hypertension (sitting diastolic BP \\> 100 or systolic \\> 180) or proliferative retinopathy\n3. History of diabetes or OGTT indicative of diabetes or impaired glucose tolerance.\n4. Any history of a MI or clinically significant, active, cardiovascular history including a history of arrhythmia's or conduction delays on ECG, unstable angina, or decompensated heart failure.\n5. Any laboratory values: AST \\> 2x ULN; ALT \\> 2x ULN TSH \\> 6 mU/l\n6. Current addiction to alcohol or substances of abuse as determined by the investigator.\n7. Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation\n8. Taking any prescription or non-prescription medications at the time of the study\n9. Having donated blood three months prior to and three months post study procedures\n10. A pregnancy test will be performed 1 to 3 days prior to each study in all female subjects. Those who test positive for pregnancy will be excluded.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Apolipoprotein B48 Production Rate After Acute Oral Administration of 100mg Sitagliptin (Compared to Placebo)","description":"Apolipoprotein B48 turnover was measured in a 10-hour kinetic study with in vivo tracer techniques and mathematical modeling to calculate production rates. Studies were performed under conditions of a pancreatic clamp and a steady state fed state in volunteers receiving single oral dose of either 100mg sitagliptin or matching placebo.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"122.9","spread":"30.4"},{"groupId":"OG001","value":"60.6","spread":"12.2"}]}]}]},{"type":"SECONDARY","title":"Apolipoprotein B100 Production Rate After Acute Oral Administration of 100mg Sitagliptin (Compared to Placebo)","description":"Apolipoprotein B100 turnover was measured in a 10-hour kinetic study with in vivo tracer techniques and mathematical modeling to calculate production rates. Studies were performed under conditions of a pancreatic clamp and a steady state fed state in volunteers receiving single oral dose of either 100mg sitagliptin or matching placebo.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":"1.8"},{"groupId":"OG001","value":"20.4","spread":"2.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":[]}}}